SCHEMBL7555707

SCHEMBL7555707

COc1ccc(S(=O)(=O)C2CCN(Cc3ccccc3)C(C(=O)O)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
LMNA P02545 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MMP13 P45452 5/20 0.49
MMP1 P03956 5/20 0.49
MMP9 P14780 4/20 0.49
MMP3 P08254 2/20 0.49
MMP7 P09237 2/20 0.49
HTR2A P28223 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ELOVL6 Q9H5J4 1/20 0.46
MMP8 P22894 2/20 0.46
MMP2 P08253 1/20 0.46
CHRM5 P08912 1/20 0.46
SIGMAR1 Q99720 3/20 0.45
PKM P14618 2/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7548378 0.92 MMP13 (0.46) ALDH1A1KDM4EMMP13MMP1MMP9
SCHEMBL7555081 0.91 MMP13 (0.47) ALDH1A1LMNAKDM4EMMP13MMP1
SCHEMBL7505164 0.90 MMP1 (0.58) MMP13MMP1MMP9MMP3MMP7
Hydroxyamine SCHEMBL7557417 0.89 MMP13 (0.46) ALDH1A1LMNAKDM4EMMP13MMP1
SCHEMBL7518010 0.88 S1PR5 (0.50) MMP13MMP1MMP9HTR2ASMN1; SMN2
SCHEMBL7550528 0.88 MMP1 (0.53) ALDH1A1LMNAKDM4EMMP13MMP1
SCHEMBL7510199 0.88 KCNH2 (0.51) MMP13MMP1MMP9MMP3HTR2A
SCHEMBL7511232 0.88 S1PR5 (0.48) ALDH1A1LMNAMMP13MMP1MMP9
SCHEMBL7555310 0.88 MMP8 (0.46) ALDH1A1LMNAMMP13MMP1MMP9
Hydroxyamine SCHEMBL7641818 0.87 NPC1 (0.48) MMP13MMP1MMP9HTR2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006922-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors AMERICAN CYANAMID COMPANY (US) 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006922-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors MMP12, ADAM33, MMP2 ALDH1A1 3024/4885LMNA 3266/4885KDM4E 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.